ES2099747T3 - THERAPEUTICALLY EFFECTIVE TOPIC APPLICATION OF ST1435. - Google Patents

THERAPEUTICALLY EFFECTIVE TOPIC APPLICATION OF ST1435.

Info

Publication number
ES2099747T3
ES2099747T3 ES91912052T ES91912052T ES2099747T3 ES 2099747 T3 ES2099747 T3 ES 2099747T3 ES 91912052 T ES91912052 T ES 91912052T ES 91912052 T ES91912052 T ES 91912052T ES 2099747 T3 ES2099747 T3 ES 2099747T3
Authority
ES
Spain
Prior art keywords
therapeutically effective
topic application
skin
effective topic
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91912052T
Other languages
Spanish (es)
Inventor
Alfred Moo-Young
Ana Zepeda-Ortega
Horacio Bruno Croxatto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Population Council Inc
Original Assignee
Population Council Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Population Council Inc filed Critical Population Council Inc
Application granted granted Critical
Publication of ES2099747T3 publication Critical patent/ES2099747T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

16-methylene-17 alpha -acetoxy-19-nopregnene-3,20-dione (ST1435) can be formulated for hormonal therapy by transdermal application to provide sustained blood release through the skin into the blood so as to provide pharmaceutically effective serum levels of ST1435 without occluding the skin.
ES91912052T 1990-06-01 1991-05-24 THERAPEUTICALLY EFFECTIVE TOPIC APPLICATION OF ST1435. Expired - Lifetime ES2099747T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53221590A 1990-06-01 1990-06-01

Publications (1)

Publication Number Publication Date
ES2099747T3 true ES2099747T3 (en) 1997-06-01

Family

ID=24120850

Family Applications (2)

Application Number Title Priority Date Filing Date
ES91912052T Expired - Lifetime ES2099747T3 (en) 1990-06-01 1991-05-24 THERAPEUTICALLY EFFECTIVE TOPIC APPLICATION OF ST1435.
ES96201585T Expired - Lifetime ES2180690T3 (en) 1990-06-01 1991-05-24 PREPARATION OF COMPOSITIONS THAT INCLUDE ST1435 FOR TOPICAL APPLICATION.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96201585T Expired - Lifetime ES2180690T3 (en) 1990-06-01 1991-05-24 PREPARATION OF COMPOSITIONS THAT INCLUDE ST1435 FOR TOPICAL APPLICATION.

Country Status (10)

Country Link
US (1) US5651973A (en)
EP (3) EP1093816A3 (en)
JP (1) JP2625254B2 (en)
AT (2) ATE220912T1 (en)
CA (1) CA2083404C (en)
DE (2) DE69133077T2 (en)
DK (2) DK0600873T3 (en)
ES (2) ES2099747T3 (en)
GR (1) GR3023312T3 (en)
WO (1) WO1991018570A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1093816A3 (en) * 1990-06-01 2003-10-22 The Population Council, Inc. Use of ST1435 in hormonal therapy by transdermal application
US6197327B1 (en) 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
FR2776191B1 (en) * 1998-03-23 2002-05-31 Theramex TOPICAL HORMONAL COMPOSITION WITH SYSTEMIC EFFECT
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US8529807B2 (en) * 2002-01-17 2013-09-10 Lts Lohmann Therapie-Systeme Ag Method for neutralizing or recycling carrier materials for film-like coatings
GB2389793A (en) * 2002-06-18 2003-12-24 Euro Celtique Sa Transdermal delivery system
US20040057983A1 (en) * 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
ES3012497T3 (en) 2005-10-12 2025-04-09 Besins Healthcare Lu Sarl Improved testosterone gel and method of use
US8602961B2 (en) 2008-05-15 2013-12-10 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
WO2010019365A1 (en) * 2008-08-12 2010-02-18 Optimer, Inc. Method of reducing the distortion of the electromagnetic field
EP2512486B1 (en) 2009-12-17 2017-06-28 The Population Council, Inc. Nestorone®/estradiol transdermal gel
US10888707B2 (en) 2013-03-19 2021-01-12 Genovus Biotechnologies Inc. Muscle optimization device and method
US10322063B2 (en) 2013-03-19 2019-06-18 Genovus Biotechnologies Inc. Muscle optimization device and method
PT3224410T (en) 2014-11-25 2019-07-16 Buckman Laboratories Int Inc Felt conditioner and cleaner

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1543245C3 (en) * 1965-11-26 1974-07-18 Merck Patent Gmbh, 6100 Darmstadt 16-Methy len-19-norprogesterone derivatives, processes for their production and pharmaceutical preparations containing them
NL6902314A (en) * 1969-02-13 1970-08-17
US3948262A (en) * 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4292965A (en) * 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4834978A (en) * 1984-10-01 1989-05-30 Biotek, Inc. Method of transdermal drug delivery
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
AU607172B2 (en) * 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
CH674618A5 (en) * 1987-04-02 1990-06-29 Ciba Geigy Ag
HU210549B (en) * 1988-10-27 1995-05-29 Schering Ag Process for producing transdermally applicable pharmaceutical composition containing gestodene
EP1093816A3 (en) * 1990-06-01 2003-10-22 The Population Council, Inc. Use of ST1435 in hormonal therapy by transdermal application
WO1991018572A1 (en) * 1990-06-01 1991-12-12 Robertson, Dale, N. Device for transdermal administration of drugs
US5122382A (en) * 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices

Also Published As

Publication number Publication date
EP0754456B1 (en) 2002-07-24
DE69133077T2 (en) 2002-11-07
EP0754456A3 (en) 2000-02-02
ES2180690T3 (en) 2003-02-16
JPH07502253A (en) 1995-03-09
JP2625254B2 (en) 1997-07-02
ATE220912T1 (en) 2002-08-15
EP1093816A2 (en) 2001-04-25
CA2083404A1 (en) 1991-12-02
DE69125855T2 (en) 1997-07-31
EP0600873B1 (en) 1997-04-23
DK0600873T3 (en) 1997-05-20
ATE151977T1 (en) 1997-05-15
US5651973A (en) 1997-07-29
CA2083404C (en) 2001-02-20
EP0600873A1 (en) 1994-06-15
EP0600873A4 (en) 1993-09-02
DE69125855D1 (en) 1997-05-28
GR3023312T3 (en) 1997-08-29
EP1093816A3 (en) 2003-10-22
EP0754456A2 (en) 1997-01-22
DE69133077D1 (en) 2002-08-29
WO1991018570A1 (en) 1991-12-12
DK0754456T3 (en) 2002-11-11

Similar Documents

Publication Publication Date Title
World Health Organization The World health report: 1997: Conquering suffering, enriching humanity
ES2099747T3 (en) THERAPEUTICALLY EFFECTIVE TOPIC APPLICATION OF ST1435.
DK0502092T3 (en) Oral preparation for the treatment of inflammatory bowel diseases
RU94038043A (en) Use of the substituted adenine derivatives for multiple sclerosis treatment
HUP0104795A2 (en) Azabicycloalkanes as ccr5 modulators, pharmaceutical compositions comprising thereof and their use
TR200101859T2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
SE9702860D0 (en) New use
ES550011A0 (en) A METHOD OF ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF TIMOLOL
DE69935720D1 (en) DIAMINO-PROPANOL COMPOUNDS FOR THE TREATMENT OF ISCHEMAS
SE8406538D0 (en) NOVEL DERIVATIVES OF PURINE
FI963049L (en) Progesterone antagonists for the manufacture of medicinal products intended for the treatment of bleeding due to uterine dysfunction
EE200200107A (en) Use of a fast-acting selective serotonin reuptake inhibitor in the manufacture of a medicament for the treatment of sexual dysfunction
DK1383540T3 (en) Methods and pharmaceutical compositions for wound healing
ES2173858T3 (en) ANALOGS OF HUPERZINA A.
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
EA199800717A1 (en) METHOD FOR THE TREATMENT OF MAMMAL DISEASES AND THE CYVITTERION COMPOSITION
FI953565A7 (en) New anticoagulant cofactor activity
DK0817646T3 (en) Methods for treating inflammation and preparations therefore
DK0862454T3 (en) CTLA-8 in combination with G-CSF or with G-CSF and IL-6 and use of CTLA-8 to treat infections
SE9904289D0 (en) Method and camposition for the treatment of adenoviral ocular infections
EP1152760A4 (en) USE OF 4-AMINO PYRIDINE FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES
WO2001041771A3 (en) Transdermal system containing acetylsalicylic acid for treatment of migraine
DK1150981T3 (en) Therapeutic necleoside compound
MX9602996A (en) Benzothiophene, benzofuran and indolethiazepinones, oxazepinones and diazepinones as inhibitors of cell adhesion and as inhibitors of hiv.
JPS53107478A (en) Purification of urokinase

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 600873

Country of ref document: ES